Apellis Pharmaceuticals: Continued EMPAVELI Expansions Beyond PNH And C3G-Disorders

Group 1 - The article discusses Apellis Pharmaceuticals and its potential market position in the treatment of rare kidney diseases [2] - The author runs a pharmaceutical analysis service that provides in-depth research on various biotech companies, including a model portfolio of small and mid-cap stocks [2] - The service offers a subscription model with a promotional free trial and discounted yearly plan [1] Group 2 - The article emphasizes the importance of data from Apellis regarding rare kidney diseases, suggesting it may lead to a first-to-market advantage [2]